Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Marstacimab (Hympavzi, Pfizer) is indicated for 'routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: severe haemophilia A (congenital factor ...

Emerito Carlos Rodriguez-Merchan Disclosures Expert Rev Hematol. 2013;6 (6):637-642.

The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease immunoglobulin A nephropathy (IgAN).

Pfizer’s stock showed signs of life, closing at $24.74 with a +1.04% gain, adding to its recent short-term momentum. This week alone, shares are up over 6%, and they’ve gained more than 8% in the past ...

Pfizer faces its share of challenges, including declining sales of its COVID-19 products, U.S. Medicare Part D headwinds, the upcoming loss of exclusivity cliff, uncertainties around tariffs and a ...

New data released from Spherix Global Insights highlights exciting opportunities in both EU and US for launch brands Hympavzi (Pfizer), Alhemo (Novo Nordisk), Qfitlia (Sanofi) and others, along ...